Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors.
This study highlights the potential of macrocyclic peptides as selective ligands for melanocortin receptors, particularly hMC4R, but lacks detailed quantitative results.
Where it sits
this study against the rest of the setmelanotide corpusSummary and findings
This study designed and synthesized a series of 14 macrocyclic peptide analogs targeting human melanocortin receptors. The pharmacological activities were assessed, revealing that compounds FM648 and FM636 acted as potent and selective hMC4R antagonists. Additionally, FM635 showed agonist activity with selectivity for the hMC4R receptor.
Abstract
The recent clinical success of macrocyclic peptides, such as bremelanotide and setmelanotide, highlights the potential of this modality as a "Goldilocks" chemical class, effectively balancing the properties of small molecules and biologics while optimizing their affinity, stability, and pharmacokinetics. Despite their potential, achieving selective MCR targeting with optimal pharmacological profiles remains challenging. Motivated by these considerations, we designed and synthesized a series of 14 macrocyclic peptide analogs (19-23-membered rings) based on MT-II, SHU-9119, and PG-901 scaffolds. Their pharmacological activities were assessed using human MC1R, MC3R, MC4R, and MC5R. The novel macrocyclic compounds FM648 and FM636 emerged as potent and selective hMC4R antagonists. Additionally, FM635 exhibited interesting agonist activity with remarkable selectivity for the same receptor. This study underscores the potential of tailored midsized macrocycles as selective MCR ligands and provides new insights into the structure-activity relationships, thereby guiding the development of therapeutic candidates for metabolic and inflammatory diseases.
Background
This paper addresses the challenge of selectively targeting human melanocortin receptors (MCRs) with macrocyclic peptides. Previous research has indicated that macrocyclic peptides, like bremelanotide and setmelanotide, can balance the properties of small molecules and biologics. The study is significant as it explores the design of new macrocyclic compounds that may improve pharmacological profiles for therapeutic applications.
Methods
The study involved the design and synthesis of 14 macrocyclic peptide analogs with 19-23 membered rings. The pharmacological activities of these compounds were assessed using human MC1R, MC3R, MC4R, and MC5R. Specific details on population, n, dose, duration, and outcome measures were not reported in the abstract.
Results
The primary observation was that FM648 and FM636 were identified as potent and selective hMC4R antagonists. The study also noted that FM635 showed agonist activity with selectivity for hMC4R. Specific numeric findings, effect sizes, p-values, and confidence intervals were not reported in the abstract.
Interpretation
The findings suggest that the newly designed macrocyclic compounds may offer improved selectivity for MCRs compared to previous compounds. However, without specific numeric data, it is difficult to assess the clinical significance of these findings. The study does not report potential confounds such as sample size or funding sources, which limits the conclusions that can be drawn.
Key findings
- FM648 and FM636 emerged as potent and selective hMC4R antagonists.
- FM635 exhibited interesting agonist activity with remarkable selectivity for hMC4R.
- 14 macrocyclic peptide analogs were synthesized based on MT-II, SHU-9119, and PG-901 scaffolds.
Limitations
- Specific numeric findings and statistical data not reported.
- Details on study design, population, and outcome measures not provided.
- Potential confounds such as sample size and funding sources not discussed.